Description
Created On: 2020-07-15
Record Count: 5
Primary Industries
- Drugs
- Disease
- Therapeutic
- cardiac
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 245896
Commercialization of the Product in the Field in the Licensee Territory.
Compound means the compound identified by the International NonProprietary Name avanafil and chemically known as (S)-4-(3-Chloro-4-methoxybenzylamino)-2-(2-hydroxymethylpyrrolidin-1-yl)-N-pyrimidin-2-ylmethyl-5-pyrimidinecarboxyamide, including any metabolites, polymorphs, salts, esters, free acid forms, free base forms, pro-drug forms, racemates and all optically active forms thereof.
Product means pharmaceutical compositions containing the Compound, including but not limited to that drug product known as STENDRA â„¢, in the form, formulation, and dosage strength(s) as defined in the NDA approved by the FDA as of the Effective Date and any other improvements, line extensions, delivery mechanisms, dosage strengths, formulations, or forms as may be approved in the future by the FDA or Health Canada that, in each case, contain a Compound.
Licensor Trademarks means the mark STENDRA.
STENDRA is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity.
IPSCIO Record ID: 237221
For the Non-Exclusive License Grant, in the event that the discovery, development, making, having made, importing, exporting, use, distribution, marketing, promotion, offering for sale or sale by Licensee, its Affiliates and/or sublicensees of Licensed Compounds and/or Licensed Products would infringe during the Term of this Agreement a claim of an issued patent, and/or any patent rights which Licensor owns or has the rights to license and which patents are not covered by the exclusive grant, Licensor grants, to the extent Licensor is legally able to do so, a non-exclusive license in the Territory under such issued patents solely for Licensee, its Affiliates and/or sublicensees to discover, develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell Licensed Compounds and/or Licensed Products in the Field in the Territory.
Licensed Products shall mean any form or dosage of pharmaceutical compositions or preparations, including, without limitation, Licensee Combination Products, in final form for sale by prescription, over-the-counter or any other method, which contain as an active ingredient the Licensed Compound. Licensed Products shall not include Licensor Combination Products, injectable formulations of pharmaceutical compositions containing, as an active ingredient, the Licensed Compound or vaginal suppository formulations containing, as an active ingredient, the Licensed Compound.
The patents relate to male sexual function methods and formulation for modulating the human sexual response.
Licensed Product relates to Vasomax product for the treatment of male erectile dysfunction. Vasomax(TM) is an oral treatment for male erectile dysfunction, commonly referred to as impotence.
IPSCIO Record ID: 263955
Cancer Field means the prophylactic or therapeutic administration to humans or non-human animals as an agent, either alone or in combination with other agents, for the prevention, treatment or palliation of cancer including neoadjuvant, adjuvant or supportive care and/or as part of combination with radiotherapy, surgery, chemo-, biologic- or other therapy associated with cancer, including, but not limited to, pain and bone/skeletal complications or indications from bone metastasis.
IPSCIO Record ID: 279309
Licensor grants a non-exclusive, royalty free license to use Licensors corporate Trademarks solely for purposes of Commercializing Products, which license shall terminate upon the expiration or earlier termination of this Agreement for any reason.
Compound means AGI-1067, which is chemically defined as Butanedioic acid, including its pharmacologically acceptable salts, solvates, hydrates, hemihydrates, polymorphs, metabolites; free base forms, pro-drugs, esters, tautomers and if applicable, any isomers, stereoisomers, racemates, enantiomers and all optically active forms thereof.
AGI-1067 is a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque.
IPSCIO Record ID: 233451
The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.
The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.
The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.
Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.
